A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT01321554
First received: March 10, 2011
Last updated: April 18, 2014
Last verified: April 2014

March 10, 2011
April 18, 2014
May 2011
January 2015   (final data collection date for primary outcome measure)
To compare the Progression-free Survival (PFS) of subjects with 131IRefractory differentiated thyroid cancer (DTC) with radiographic evidence of disease progression within the prior 12 months treated with lenvatinib versus Placebo. [ Time Frame: Date of randomization to the date of disease progression (measured every 8 weeks) or death (whichever occurs first) as determined by blinded independent imaging review ] [ Designated as safety issue: No ]
To compare the Progression-free Survival (PFS) of subjects with 131IRefractory differentiated thyroid cancer (DTC) with radiographic evidence of disease progression within the prior 12 months treated with E7080 versus Placebo. [ Time Frame: Date of randomization to the date of disease progression (measured every 8 weeks) or death (whichever occurs first) as determined by blinded independent imaging review ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01321554 on ClinicalTrials.gov Archive Site
To compare Overall Response Rate (ORR) (Complete and Partial Responses, CR and PR) of subjects treated with lenvatinib versus Placebo. [ Time Frame: Date of randomization to the date of disease progression (measured every 8 weeks) or death ] [ Designated as safety issue: No ]
To compare Overall Response Rate (ORR) (Complete and Partial Responses, CR and PR) of subjects treated with E7080 versus Placebo. [ Time Frame: Date of randomization to the date of disease progression (measured every 8 weeks) or death ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

This is a multicenter, randomized, double-blind, Placebo-controlled Phase 3 study to compare the PFS of subjects with 131I-refractory DTC and radiographic evidence of disease progression within the prior 12 months, treated with E7080 (lenvatinib) 24 mg by continuous once daily (QD) oral dosing versus Placebo.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Thyroid Cancer
  • Drug: lenvatinib 24 mg administered orally, once a day
    Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label lenvatinib and enter the Optional Open Label lenvatinib Treatment Period of the Extension Phase. Subjects who request to receive open label lenvatinib(at the time of confirmed progression) will be informed whether they received placebo or lenvatinib during the period of blinded study drug administration.. Subjects who received lenvatinib will not be eligible for the open-label phase.
    Other Names:
    • lenvatinb
    • E7080
  • Drug: Placebo 24mg administered orally, once a day
    Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label lenvatinib and enter the Optional Open Label lenvatinib Treatment Period of the Extension Phase. Subjects who request to receive open label lenvatinib ( at the time of confirmed progression) will be informed whether they received placebo or lenvatinib during the period of blinded study drug administration.
  • Experimental: lenvatinib
    Intervention: Drug: lenvatinib 24 mg administered orally, once a day
  • Experimental: Placebo
    Intervention: Drug: Placebo 24mg administered orally, once a day
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
392
March 2015
January 2015   (final data collection date for primary outcome measure)

INCLUSION

  1. Subjects must have histologically or cytologically confirmed diagnosis of one of the following differentiated thyroid cancer (DTC) subtypes:

    a. Papillary thyroid cancer (PTC) i. Follicular variant ii. Variants (including but not limited to tall cell, columnar cell, cribriform-morular, solid, oxyphil, Warthin's-like, trabecular, tumor with nodular fasciitis-like stroma, Hürthle cell variant of papillary carcinoma, poorly differentiated) b. Follicular thyroid cancer (FTC) i. Hürthle cell ii. Clear cell iii. Insular

  2. Measurable disease meeting the following criteria and confirmed by central radiographic review:

    1. At least 1 lesion of ≥ 1.0 cm in the longest diameter for a non-lymph node or ≥ 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 using computerized tomography/magnetic resonance imaging (CT/MRI). If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of ≥ 1.5 cm
    2. Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion
  3. Subjects must show evidence of disease progression within 12 months (an additional month will be allowed to accommodate actual dates of performance of screening scans, i.e., within ≤ 13 months) prior to signing informed consent, according to RECIST 1.1 assessed and confirmed by central radiographic review of CT and / or MRI scans
  4. Subjects must be 131I-refractory / resistant as defined by at least one of the following:

    1. One or more measurable lesions that do not demonstrate iodine uptake on any radioiodine scan
    2. One or more measurable lesions that has progressed by RECIST 1.1 within 12 months of 131I therapy, despite demonstration of radioiodine avidity at the time of that treatment by pre- or post-treatment scanning. These subjects must not be eligible for possible curative surgery
    3. Cumulative activity of 131I of > 600 mCi or 22 gigabequerels (GBq), with the last dose administered at least 6 months prior to study entry
  5. Subjects may have received 0 or 1 prior VEGF / VEGFR-targeted therapy ( for example sorafenib, sunitinib, pazopanib, etc.)
  6. Subjects with known brain metastases who have completed whole brain radiotherapy, stereotactic radiosurgery or complete surgical resection, will be eligible if they have remained clinically stable, asymptomatic and off of steroids for one month
  7. Subjects must be receiving thyroxine suppression therapy and thyroid stimulating hormone (TSH) should not be elevated (TSH should be ≤ 5.50 mcu/mL). When tolerated by the subject, thyroxine dose should be changed to achieve TSH suppression (TSH < 0.50 mcu/mL) and this dose can be changed concurrently upon starting lenvatinib
  8. All chemotherapy or radiation-related toxicities must have resolved to < Grade 2 severity, except alopecia and infertility
  9. Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 − 2
  10. Adequately controlled blood pressure with or without antihypertensive medications, defined as BP < 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to Cycle 1 Day 1
  11. Adequate renal function defined as calculated creatinine clearance ≥ 30 mL/min per the Cockcroft and Gault formula
  12. Adequate bone marrow function:

    1. Absolute neutrophil count (ANC) ≥ 1500/mm3 (≥ 1.5 × 103/μL)
    2. Platelets ≥ 100,000/mm3 (≥ 100 × 109/L)
    3. Hemoglobin ≥ 9.0 g/dL
  13. Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ≤ 1.5
  14. Adequate liver function:

    1. Bilirubin ≤ 1.5 × the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia or Gilbert's syndrome
    2. Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN if subject has liver metastases). if alkaline phosphatase is > 3 × ULN (in absence of liver metastases) or > 5 × ULN (in presence of liver metastases) AND the subject also is known to have bone metastases, the liver-specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of total alkaline phosphatase
  15. Males or females age ≥ 18 years at the time of informed consent
  16. All females must have a negative serum or urine pregnancy test. Females of childbearing potential and male subjects who are partners of women of childbearing potential must use or their partners must use a highly effective method of contraception
  17. Voluntary provision of written informed consent and the willingness and ability to comply with all aspects of the protocol

EXCLUSION

  1. Anaplastic or Medullary carcinoma of the thyroid
  2. Two or more prior VEGF / VEGFR-targeted therapies or any ongoing treatment for 131I-refractory DTC other than TSH-suppressive thyroid hormone therapy
  3. Prior treatment with lenvatinib (E7080)
  4. Subjects who have received any anti-cancer treatment within 21 days or any investigational agent within 30 days prior to the first dose of study drug and should have recovered from any toxicity related to previous anti-cancer treatment. This does not apply to the use of TSH-suppressive thyroid hormone therapy
  5. Major surgery within 3 weeks prior to the first dose of study drug
  6. Subjects having > 1+ proteinuria on urine dipstick testing will undergo 24h urine collection for quantitative assessment of proteinuria. Subjects with urine protein ≥ 1 g/24h will be ineligible
  7. Gastrointestinal malabsorption, or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib (E7080). Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina; myocardial infarction or stroke within 6 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment

9. Prolongation of QTc interval to > 480 msec 10. Bleeding or thrombotic disorders or use of anticoagulants, such as warfarin, or similar agents requiring therapeutic international normalized ration (INR) monitoring. (Treatment with low molecular weight heparin (LMWH) is allowed) 11. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug 12. Active infection (any infection requiring treatment) 13. Active malignancy (except for differentiated thyroid carcinoma, or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 24 months 14. Known intolerance to any of the study drugs (or any of the excipients) 15. Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial 16. Females who are pregnant or breastfeeding

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Argentina,   Australia,   Austria,   Belgium,   Brazil,   Canada,   Chile,   Czech Republic,   Denmark,   France,   Germany,   Italy,   Japan,   Korea, Republic of,   Poland,   Portugal,   Romania,   Russian Federation,   Spain,   Sweden,   Thailand,   United Kingdom
 
NCT01321554
E7080-G000-303
Yes
Eisai Inc.
Eisai Inc.
Not Provided
Study Director: Eisa Inc Eisai Inc.
Eisai Inc.
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP